Can a pharmacy still compound bio-identical hormone therapy for me?

Yes — pharmacists can still compound menopausal hormone preparations for an individual patient who has a specific clinical need not met by a registered product. The key requirement is that the compounding is for you specifically, on a practitioner's request, not made speculatively or in bulk. This pathway remains lawful under the May 2026 guidance.

Is compounded semaglutide still available in Australia?

Compounded GLP-1 receptor agonist analogues are now in the TGA's higher-risk category, which means the prescribing doctor and compounding pharmacist carry more documentation obligations — not that the pathway is closed. Whether your preparation remains accessible depends on prescriber and pharmacy willingness to meet the new requirements. Ask your prescribing GP directly.

TGA sets clearer rules on compounded medicines — what patients need to know

What just happened

The Therapeutic Goods Administration published new guidance in May 2026 clarifying the legal requirements for manufacturing, supplying, and advertising compounded medicines in Australia. Compounded medicines — preparations made by a pharmacist or registered health practitioner to meet an individual patient’s specific clinical need — are a significant part of integrative, specialist, and palliative care in this country. Particular relevance to patients managing hormonal imbalances, rare conditions, dysphagia, or treatment-resistant presentations where registered products don’t fit.

The guidance consolidates existing law rather than introducing new restrictions. The core legal principle remains: a compounded medicine is exempt from the Australian Register of Therapeutic Goods when it is prepared for a specific individual patient, on a practitioner’s request, for that patient’s use. The exemption does not extend to speculative or bulk preparation. Anticipatory compounding — making batches in advance without a specific patient prescription — remains lawful only in limited hospital settings.

What the guidance adds is a formalised category of “higher-risk compounded products” that carry additional documentation and oversight requirements. These include GLP-1 receptor agonist analogues (semaglutide and tirzepatide preparations compounded during the ongoing access issues), medicinal cannabis preparations beyond those already registered, biological therapies, and intravenous therapies. For patients in any of these categories, the GP and pharmacy involved now face a more explicit documentation standard.

The both-and

Clarity is genuinely useful for practitioners. Clarity has access consequences for some patients. Both are true.

Compounding sits in a legally complex and clinically important space. The TGA framework has always recognised that registered medicines cannot meet every patient’s individual clinical need — formulation differences, dosage variations outside commercial ranges, constituent allergies, discontinued products. Compounding fills those gaps. The guidance affirms this pathway clearly and without ambiguity.

The harder tension is what the GLP-1 story illustrates. During the semaglutide access issues of 2024 to 2026, a significant number of patients were accessing compounded preparations because the registered product was unavailable or unaffordable. Some of those preparations were appropriate individual-patient compounding. Some were operating at industrial scale while nominally meeting the individual-prescription requirement on paper. The RAPS Asia-Pacific coverage noted that the guidance appears designed in part to close the gap between the letter and the spirit of the exemption — to prevent scale-compounding from sheltering behind individual-prescription paperwork.

Where this becomes uncomfortable for patients: people who have accessed compounded GLP-1 preparations, compounded menopausal hormone therapies in non-standard formulations, or specific medicinal cannabis preparations for treatment-resistant conditions are not primarily concerned with industrial-scale operators. They are managing their own health through a pathway that worked for them. When the compliance burden on that pathway increases, the first practical consequence is often access reduction — not because large operators disappear, but because smaller prescribers and compounding pharmacies find the documentation requirements not worth their volume.

The guidance is not a ban on compounding. It is the existing law made legible and enforceable. The difference in practice will depend on how TGA prosecutes the higher-risk category over the next 12 months.

2 cents

Three specific things for anyone on or considering compounded medicines.

Compounded hormone therapy: the individual-patient HRT pathway — your GP prescribes for your specific clinical need, a compounding pharmacy prepares to that prescription — remains lawful under this guidance. The requirement is that it is genuinely for you specifically, not prepared speculatively or in bulk. If your GP or compounding pharmacy is uncertain, the TGA guidance document is the reference to read together.

Compounded GLP-1 analogues: this category is now explicitly named as higher-risk. It does not mean the preparation is illegal; it means the documentation behind the prescription should be more thorough and the clinical rationale clearly recorded. If you are on a compounded semaglutide or tirzepatide preparation, confirm with your prescribing GP that they are aware of the new oversight requirements and that the pathway is still intact.

Medicinal cannabis: most medicinal cannabis patients in Australia are already on TGA-approved pathways (Special Access Scheme or Authorised Prescribers). If you are on a compounded cannabis preparation that falls outside the registered range, confirm with your prescriber that the current supply arrangement meets the new guidance requirements.

The practical question for most patients: “Is my preparation covered by an individual patient prescription, written for me, by my doctor, for my specific need?” If yes, the guidance changes documentation requirements for the practitioner, not the fundamental availability for the patient.

This is general information. Compounding decisions involve prescriber judgement, pharmacist assessment, individual clinical needs, and TGA compliance — none of which can be navigated through an article. Your GP is the right person for the specific question.

Verdict

Verdict: maybe — watch this.

The TGA guidance formalises rules that have always existed but were unevenly enforced. For patients on compounded preparations — particularly GLP-1 analogues, medicinal cannabis, and non-standard hormone therapies — the higher-risk category creates additional documentation obligations on practitioners. Access is not blocked; it is formalised. Whether that formality is practically navigable depends on your prescriber and compounding pharmacy. If you are in any of these categories, that conversation with your GP is worth having now rather than when the question becomes urgent.